Marlowe J. Schneidkraut
Marlowe J. Schneidkraut has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anne-Hortense Schmitt-Hoffmann
Basilea Pharmaceutica International Ltd., Basel, Switzerland
1 shared publication- Cees Korstanje
Astellas Pharma Europe B.V.
1 shared publication - David R. Andes
Department of Medicine, University of Wisconsin-Madison
1 shared publication - Gan-Xin Yan
Main Line Health Heart Center and Lankenau Institute for Medical Research
1 shared publication Jochen Spickermann
Basilea Pharmaceutica International Ltd., Basel, Switzerland
1 shared publication- Koichiro Yuno
Drug Safety Research Laboratories, Astellas Pharma Inc., Ibaraki, Japan
1 shared publication
Latest Publications
- Open Access
- 1 December 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (12)
Tissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
Quantitative whole-body autoradiography was used to assess the distribution and tissue penetration of isavuconazole in rats following single and repeated oral-dose administration of radiolabeled isavuconazonium sulfate, the prodrug of isavuconazole. Following a single-dose administration of radiolabeled isavuconazonium sulfate (labeled on the active moiety), radioactivity was detectable within 1 h postdose in 56 of 65 tissue/fluid specimens. The highest maximum concentrations (Cmax) were observed in bile and liver (66.6 and 24.7 μg eq/g, respectively). The lowestCmaxvalues were in bone and eye lens (0.070 and 0.077 μg eq/g, respectively). By 144 h postdose, radioactivity was undetectable in all tissues/fluids except liver (undetectable at 336 h) and adrenal gland tissues (undetectable at 672 h). Following daily administration for up to 21 days, 1-h-postdoseCmaxvalues were the highest on or before day 14 in all except seven tissues/fluids, of which only rectum mucosa and small intestine mucosa hadCmaxvalues >25% higher than all other 1-h-postdose values. For 24-h-postdoseCmaxvalues, only large intestine, large intestine mucosa, and urine had the highestCmaxvalues at day 21. The penetration of single oral doses of unlabeled isavuconazole (25 mg/kg of body weight isavuconazonium sulfate) and voriconazole (50 mg/kg) into rat brain (assessed using liquid chromatography-tandem mass spectrometry) was also compared. Brain concentration/plasma concentration ratios reached approximately 1.8:1 and 2:1, respectively. These data suggest that isavuconazole penetrates most tissues rapidly, reaches a steady state in most or all tissues/fluids within 14 days, does not accumulate in tissues/fluids over time, and achieves potentially efficacious concentrations in the brain.
- 1 December 2017
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (12)
Open AccessTissue Distribution and Elimination of Isavuconazole following Single and Repeat Oral-Dose Administration of Isavuconazonium Sulfate to Rats
Quantitative whole-body autoradiography was used to assess the distribution and tissue penetration of isavuconazole in rats following single and repeated oral-dose administration of radiolabeled isavuconazonium sulfate, the prodrug of isavuconazole. Following a single-dose administration of radiolabeled isavuconazonium sulfate (labeled on the active moiety), radioactivity was detectable within 1 h postdose in 56 of 65 tissue/fluid specimens. The highest maximum concentrations (Cmax) were observed in bile and liver (66.6 and 24.7 μg eq/g, respectively). The lowestCmaxvalues were in bone and eye lens (0.070 and 0.077 μg eq/g, respectively). By 144 h postdose, radioactivity was undetectable in all tissues/fluids except liver (undetectable at 336 h) and adrenal gland tissues (undetectable at 672 h). Following daily administration for up to 21 days, 1-h-postdoseCmaxvalues were the highest on or before day 14 in all except seven tissues/fluids, of which only rectum mucosa and small intestine mucosa hadCmaxvalues >25% higher than all other 1-h-postdose values. For 24-h-postdoseCmaxvalues, only large intestine, large intestine mucosa, and urine had the highestCmaxvalues at day 21. The penetration of single oral doses of unlabeled isavuconazole (25 mg/kg of body weight isavuconazonium sulfate) and voriconazole (50 mg/kg) into rat brain (assessed using liquid chromatography-tandem mass spectrometry) was also compared. Brain concentration/plasma concentration ratios reached approximately 1.8:1 and 2:1, respectively. These data suggest that isavuconazole penetrates most tissues rapidly, reaches a steady state in most or all tissues/fluids within 14 days, does not accumulate in tissues/fluids over time, and achieves potentially efficacious concentrations in the brain.